KOD at a glance
Kodiak Sciences Inc. (KOD, SEC CIK 1468748) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Kodiak Sciences Inc. (KOD) shares worth $701.5 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by BAKER BROS. ADVISORS LP on September 29, 2026 of 1,416 shares at $85.89 per share.
- In the last 90 days, KOD insiders reported 82 open-market purchases ($157.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $157.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 82 buys · 0 sells
- Net +$157.0M
- 13F holders
- 28 funds
- $701.5M · −1 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue: precommercial biotechnology company; no quarterly revenue disclosed
- Operating loss $66.8M vs $55.5M YoY; net loss $65.6M vs $54.3M
- R&D expense $56.1M vs $42.8M, driven by KSI-101 $12.3M and KSI-501 $12.7M
- Cash position, operating cash flow, and capital deployment: no figures provided in supplied text
- DAYBREAK topline data expected September 2026; BLA submission for Zenkuda intended in 2026
Risk Factors
- No material-change statement provided; filing emphasizes continued clinical-stage status with no approved products or revenue
- Clinical efficacy risk: tarcocimab failed primary endpoints in DAZZLE, GLEAM and GLIMMER trials
- Regulatory risk: FDA may reject AI-based DAYBREAK dosing or require separate review before labeling
- Operational risk: Enrollment continues in Phase 3 PEAK, PINNACLE and ALTO trials, creating delay exposure
- Safety risk: Unexpected cataract increases observed in tarcocimab arms of GLEAM and GLIMMER trials
AI summary of the KOD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration
- Primary endpoints met for both investigational therapies, supporting potential regulatory submissions
Item EX-99.1: Item EX-99.1
- Zenkuda met DAYBREAK’s primary endpoint with p=0.0007, showing non-inferior vision gains versus aflibercept in wAMD
- 54% of Zenkuda patients reached 24-week dosing at year one under strict treat-to-dryness criteria, supporting differentiated durability
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and business highlights reported for quarter ended June 30, 2026
- Full financial details and operating developments contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $65.6M, or $1.05 per share, versus $54.3M and $1.03 in Q2 2025
- Cash $125.9M, down from $209.9M at December 31, 2025; management expects funding into 2027
Item 5.07: Submission of Matters to a Vote of Security Holders
- Class II directors Bancroft, Dahiyat, and Yang elected through 2029 annual meeting
- Bancroft received 38,940,529 votes for versus 10,560,815 withheld, signaling comparatively weaker shareholder support
AI summaries of KOD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KOD
Don't miss the next KOD filing
- Alerts as it files. A push when KOD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KOD, by share count.
- Ask anything. An AI agent that reads every KOD filing and answers with sources.
KOD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 1,416 | $85.89 |
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 619 | $84.24 |
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 1,195 | $85.40 |
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 84 | $85.89 |
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 20,031 | $85.40 |
| BAKER BROS. ADVISORS LP | Buy | Sep 29, 2026 | 10,381 | $84.24 |
| BAKER BROS. ADVISORS LP | Buy | Sep 28, 2026 | 8,021 | $64.43 |
| BAKER BROS. ADVISORS LP | Buy | Sep 28, 2026 | 479 | $64.43 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$277.3M | -$186.8M | -$234.4M |
| Net Income | -$260.5M | -$176.2M | -$230.0M |
| Balance Sheet | |||
| Total Assets | - | $335.6M | $351.5M |
| Equity | $265.8M | $150.3M | $157.4M |
| ROE | -98.0% | -117.2% | -146.1% |
| Per Share | |||
| EPS | $-4.97 | $-3.35 | $-4.32 |
| Cash Flow | |||
| Operating CF | -$154.2M | -$117.3M | -$136.0M |
| CapEx | $41.4M | $375K | $506K |
Source: XBRL data in Kodiak Sciences Inc. (KOD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KOD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $701.5M |
| Q1 2026 | 29 | $612.3M |
| Q4 2025 | 25 | $400.4M |
| Q3 2025 | 25 | $170.3M |
| Q2 2025 | 24 | $37.7M |
| Q1 2025 | 21 | $19.3M |
| Q4 2024 | 17 | $56.8M |
| Q3 2024 | 15 | $9.2M |
- T. Rowe Price Group+1.21M (+59%)
- Goldman Sachs Group+627.0K (+37%)
- Two Sigma Investments+373.5K (+376%)
- BlackRock+200.1K (+5%)
- State Street Corp+168.5K (+7%)
- Citadel Advisors LLC−713.3K (-82%)
- Invesco Ltd−230.6K (-76%)
- Renaissance Technologies LLC−105.1K (-36%)
- Morgan Stanley−80.8K (-16%)
- Northern Trust−24.5K (-6%)
- Ameriprise Financial−65.5K
- U.S. Bancorp−27
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KOD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 16, 2026 | - | - | - |
| SC 13G | Apr 2, 2026 | - | - | |
| 10-K | Mar 31, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 31, 2026 | - | - | - |
| 4 | Mar 27, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
KOD SEC filings: frequently asked questions
Are KOD insiders buying or selling?
In the last 90 days, Kodiak Sciences Inc. (KOD) officers, directors and 10% owners reported 82 open-market purchases worth $157.0 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KOD stock?
As of June 30, 2026, the largest Kodiak Sciences Inc. (KOD) holders among the 13F filers tracked by SignalX were BlackRock ($161.1 million), T. Rowe Price Group ($126.6 million), State Street Corp ($94.3 million), Goldman Sachs Group ($90.2 million), Vanguard Capital Management LLC ($70.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did KOD report in its latest 8-K?
Kodiak Sciences Inc. (KOD) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). Positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration.
What are the latest KOD SEC filings?
Kodiak Sciences Inc. (KOD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 30, 2026.
What is KOD's SEC CIK number?
Kodiak Sciences Inc. (KOD)'s SEC Central Index Key (CIK) is 1468748. EDGAR lists every KOD filing under that number.
Ask anything about KOD
The research agent reads KOD's filings, financials, insider trades and 13F holders, then answers with sources.